X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2022/10/05/2528522/0/en/atai-Life-Sciences-Announces-First-Subject-Dosed-in-Phase-1-Trial-of-Buccal-and-IV-VLS-01-a-Synthetic-Form-of-DMT.html
https://www.clinicaltrialsarena.com/news/cybin-anxiety-disorder-treatment-study/
https://www.globenewswire.com/news-release/2022/01/31/2376167/0/en/Small-Pharma-Reports-Fiscal-Third-Quarter-2021-Highlights.html
https://www.globenewswire.com/news-release/2022/01/24/2371542/0/en/Algernon-Pharmaceuticals-Discloses-Novel-Salt-Patent-Strategy-as-Part-of-its-Psychedelic-Drug-DMT-Intellectual-Property.html
https://www.globenewswire.com/news-release/2022/01/19/2369181/0/en/Algernon-Pharmaceuticals-Files-for-Clinical-Trial-and-Ethics-Approval-for-Phase-1-DMT-Human-Stroke-Study.html
https://www.biospace.com/article/entheon-biomedical-provides-update-on-clinical-and-preclinical-dmt-programs/
https://www.businesswire.com/news/home/20211024005026/en/Beckley-Psytech-Announces-First-Cohort-Dosed-in-Phase-1-Clinical-Trial-Assessing-Safety-and-Tolerability-of-Intranasal-5-MeO-DMT
https://www.globenewswire.com/news-release/2021/09/07/2292385/0/en/Algernon-Pharmaceuticals-Confirms-DMT-Increased-Growth-of-Neurons-by-40-in-Preclinical-Study-at-Sub-Hallucinogenic-Dose.html
https://www.fiercepharma.com/drug-delivery/intelgenx-inks-double-deals-to-develop-oral-film-psychedelics
Market Place
Share 
